Genocea Biosciences Receives $23,000,000 Series A Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=7cd981f9-d792-4cf5-8d52-3bf768ec2bc3&Preview=1 -
Date
2/19/2009 -
Company Name
Genocea Biosciences -
Mailing Address
161 First Street Cambridge, MA 02142 -
Company Description
Genocea was founded in 2006 based on technology from University of California at Berkeley and Harvard Medical School. Infectious diseases are the third leading cause of death each year in the United States and the world’s leading killer of children and young adults, accounting for more than 14 million deaths annually. In addition, numerous infectious diseases, while not major killers, cause chronic disability for millions and lead to tens of billions of dollars in excess healthcare costs. Many infectious diseases, such as malaria and tuberculosis (two of the top five global killers) as well as chlamydia (the most frequently reported bacterial sexually transmitted disease in the United States), are caused by pathogens that are capable of growing within human cells (intracellular pathogens). Despite the devastating health and economic impact of these diseases, and in spite of significant efforts to develop vaccines, no effective vaccines currently exist against these or a multitude of ot -
Website
http://www.genocea.com -
Transaction Type
Venture Equity -
Transaction Amount
$23,000,000 -
Transaction Round
Series A -
Proceeds Purposes
Proceeds purposes were not disclosed. -
M&A Terms
-
Venture Investor
SR One -
Venture Investor
GlaxoSmithKline -
Venture Investor
Auriga Partners -
Venture Investor
Cycad Group -
Venture Investor
Alexandria Real Estate Equities, Inc. -
Venture Investor
Lux Capital -
Venture Investor
Polaris Venture Partners -
Venture Investor
Morningside Group
